Hong Kong Stock Alert | HEARTCARE-B (06609) Surges Over 10% Before Earnings as Company Expects First Half Turnaround with Profit Exceeding RMB 40 Million

Stock News
08/29

HEARTCARE-B (06609) climbed more than 10%, and as of the time of writing, the stock was up 10.3% to HK$56.75 with a trading volume of HK$13.4465 million.

On the news front, HEARTCARE-B will hold a board meeting today to review and approve the interim results of the company and its subsidiaries for the six months ended June 30, 2025, among other matters.

The company previously announced that it expects to achieve a net profit attributable to shareholders of no less than RMB 40 million for the first half of 2025. The turnaround from loss to profit is primarily attributed to revenue growth driven by increased sales of newly launched hemorrhagic stroke treatment devices, as well as acute ischemic stroke treatment devices and other hemorrhagic stroke treatment devices. Additionally, effective cost control measures for sales costs and administrative expenses have reduced the group's overall expense ratio, while changes in the development stages of the group's R&D projects have led to decreased research and development expenditures. Fair value gains on financial assets measured at fair value through profit or loss have also increased.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10